RxDoctor Payments Data

Allison Rathan, MD

Internal Medicine · Brooklyn, NYNPI 1467447862

Payments from drug & device makers

$2,607in general payments, 2019–2025

Across 23 payments — averaging $113.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$809
  • AstraZeneca$488
  • Amgen$372
  • GSK$273
  • Merck$250
  • Medtronic$152
  • plus $264 from 3 others

What the payments were for

  • Food & beverage$2,607100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk7$809
AstraZeneca4$488
Amgen3$372
GSK3$273
Merck2$250
Medtronic1$152
Lilly USA, LLC1$125
Novartis1$120
Exact Sciences1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,607 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$20,756
Medicare patients
119
Services billed
203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide271$278,535
JardianceEmpagliflozin181$149,322
JanuviaSitagliptin Phosphate90$63,941
RybelsusSemaglutide59$56,405
TrulicityDulaglutide48$50,958
Tresiba Flextouch U-100Insulin Degludec90$41,481
MounjaroTirzepatide30$31,672
TradjentaLinagliptin17$21,003
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog73$20,945
FarxigaDapagliflozin Propanediol26$20,748
EliquisApixaban17$13,155
XareltoRivaroxaban16$8,855
Novolog FlexpenInsulin Aspart50$6,225
Semglee (Yfgn) PenInsulin Glargine-Yfgn11$4,787
Levothyroxine Sodium202$2,822

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$809$334,940330 claims
Lilly USA, LLCTrulicity, Mounjaro$125$82,63078 claims
MerckJanuvia$250$63,94190 claims
AstraZenecaFarxiga$488$20,74826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →